Folate receptor β: A novel target for therapeutic

International Journal of Clinical Rheumatology

Volumn 4, Issue 2, 2009, Pages 109-113

  Jansen, Gerrit ^a   van der Heijden, Joost W ^a   Dijkmans, Ben A C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BGC 945; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLATE RECEPTOR; FOLATE RECEPTOR BETA; FOLIC ACID ANTAGONIST; GLUCOCORTICOID; HISTONE DEACETYLASE INHIBITOR; METHOTREXATE; ONX 0801; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE INHIBITOR; POLYGLUTAMIC ACID; RETINOIC ACID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; BINDING AFFINITY; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TARGETING; DRUG UPTAKE; EDITORIAL; GENETIC POLYMORPHISM; HUMAN; LOW DRUG DOSE; MACROPHAGE ACTIVATION; NONHUMAN; PATHOGENESIS; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURINE METABOLISM; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

EID: 70949105781     PISSN: 17584272     EISSN: None     Source Type: Journal    
DOI: 10.2217/ijr.09.6     Document Type: Editorial

References (59)

1. Weinblatt ME, Trentham DE, Fraser PA et al.: Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum. 31(2), 167-175 (1988).
2. Kremer JM: Toward a better understanding of methotrexate. Arthritis Rheum. 50(5), 1370-1382 (2004).
3. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P: New therapies for treatment of rheumatoid arthritis. Lancet 370(9602), 1861-1874 (2007).
4. O'Dell JR: Therapeutic strategies for rheumatoid arthritis. N. Engl. J. Med. 350(25), 2591-2602 (2004).
5. Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH: Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann. Rheum. Dis. 60(8), 729-735 (2001).
6. Cronstein BN: Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol. Rev. 57(2), 163-172 (2005).
7. Van der Heijden JW, Dijkmans BA, Scheper RJ, Jansen G: Drug insight: resistance to methotrexate and other disease-modifying antirheumatic drugs - from bench to bedside. Nat. Clin. Pract. Rheumatol. 3(1), 26-34 (2007).
8. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP: Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J. Clin. Invest. 102(2), 322-328 (1998).
9. Dervieux T, Furst D, Lein DO et al.: Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 50(9), 2766-2774 (2004).
10. Dervieux T, Greenstein N, Kremer J: Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 54(10), 3095-3103 (2006).
11. Wessels JA, De Vries-Bouwstra JK, Heijmans BT et al.: Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum. 54(4), 1087-1095 (2006).
12. Wessels JA, van der Kooij SM, le Cessie S et al.: A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 56(6), 1765-1775 (2007).
13. Dalrymple JM, Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Barclay ML: Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 58(11), 3299-3308 (2008).
14. Fisher MC, Cronstein BN: Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J. Rheumatol. 36(6), 539-545 (2009).
15. Assaraf YG: Molecular basis of antifolate resistance. Cancer Metastasis Rev. 26(1), 153-181 (2007).
16. Wolfe F: The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin. Rheumatol. 9(4), 619-632 (1995).
17. Fleischmann RM: Is there a need for new therapies for rheumatoid arthritis? J. Rheumatol. Suppl. 73, 3-7 (2005).
18. Galindo-Rodriguez G, Aviña-Zubieta JA, Russell AS, Suarez-Almazor ME: Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study. J. Rheumatol. 26(11), 2337-2343 (1999).
19. Bingham S, Emery P: Resistant rheumatoid arthritis clinics - a necessary development? Rheumatology (Oxford) 39(1), 2-5 (2000).
20. Kremer JM: Methotrexate treatment of rheumatic diseases: can we do better? Arthritis Rheum. 58(11), 3279-3282 (2008).
21. Cannella AC, O'Dell JR: Is there still a role for traditional disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis? Curr. Opin. Rheumatol. 15(3), 185-192 (2003).
22. Fiehn C: The future of folic acid antagonist therapy in rheumatoid arthritis. Arthritis Rheum. 60(1), 1-4 (2009).
23. Fiehn C, Muller-Ladner U, Gay S et al.: Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritic drug which acts synergistically to MTX. Rheumatology (Oxford) 43(9), 1097-1105 (2004).
24. Castaneda O, Nair MG: Controlled trial of methotrexate versus CH-1504 in the treatment of rheumatoid arthritis. J. Rheumatol. 33(5), 862-864 (2006).
25. Van der Heijden JW, Oerlemans R, Dijkmans BA et al.: Folate receptor β as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum. 60(1), 12-21 (2009).
26. Qiu A, Jansen M, Sakaris A et al.: Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 127(5), 917-928 (2006).
27. Jansen G: Receptor- and carrier-mediated transport systems for folates and antifolates. In: Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy. Jackman AL (Ed.). Humana Press Inc., NJ, USA 293-321 (1999).
28. Elnakat H, Ratnam M: Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv. Drug Deliv. Rev. 56(8), 1067-1084 (2004).
29. Salazar MD, Ratnam M: The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev. 26(1), 141-152 (2007).
30. Rijnboutt S, Jansen G, Posthuma G, Hynes JB, Schornagel JH, Strous GJ: Endocytosis of GPI-linked membrane folate receptor- α. J. Cell Biol. 132(1-2), 35-47 (1996).
31. Kelemen LE: The role of folate receptor a in cancer development, progression and treatment: cause, consequence or innocent bystander? Int. J. Cancer 119(2), 243-250 (2006).
32. Wang X, Shen F, Freisheim JH, Gentry LE, Ratnam M: Differential stereospecificities and affinities of folate receptor isoforms for folate compounds and antifolates. Biochem. Pharmacol. 44(9), 1898-1901 (1992).
33. Westerhof GR, Schornagel JH, Kathmann I et al.: Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular structure and biological activity. Mol. Pharmacol. 48, 459-471 (1995).
34. Mauritz R, Peters GJ, Kathmann I et al.: Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo. Cancer Chemother. Pharmacol. 62, 937-948 (2008).
35. Ross JF, Wang H, Behm FG et al.: Folate receptor type β is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 85(2), 348-357 (1999).
36. Reddy JA, Haneline LS, Srour EF, Antony AC, Clapp DW, Low PS: Expression and functional characterization of the β-isoform of the folate receptor on CD34(+) cells. Blood 93(11), 3940-3948 (1999).
37. Wang H, Zheng X, Behm FG, Ratnam M: Differentiation-independent retinoid induction of folate receptor type β, a potential tumor target in myeloid leukemia. Blood 96(10), 3529-3536 (2000).
38. Nakashima-Matsushita N, Homma T, Yu S et al.: Selective expression of folate receptor β and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum. 42(8), 1609-1616 (1999).
39. Haringman JJ, Gerlag DM, Zwinderman AH et al.: Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 64(6), 834-838 (2005).
40. Muller C, Hohn A, Schubiger PA, Schibli R: Preclinical evaluation of novel organometallic 99mTc-folate and 99mTc-pteroate radiotracers for folate receptor-positive tumour targeting. Eur. J. Nucl. Med. Mol. Imaging 33(9), 1007-1016 (2006).
41. Turk MJ, Breur GJ, Widmer WR et al.: Folate-targeted imaging of activated macrophages in rats with adjuvant- induced arthritis. Arthritis Rheum. 46(7), 1947-1955 (2002).
42. Paulos CM, Turk MJ, Breur GJ, Low PS: Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv. Drug Deliv. Rev. 56(8), 1205-1217 (2004).
43. Leamon CP, Reddy JA, Vlahov IR et al.: Preclinical antitumor activity of a novel folate-targeted dual drug conjugate. Mol. Pharm. 4(5), 659-667 (2007).
44. Nagayoshi R, Nagai T, Matsushita K et al.: Effectiveness of anti-folate receptor β antibody conjugated with truncated Pseudomonas exotoxin in the targeting of rheumatoid arthritis synovial macrophages. Arthritis Rheum. 52(9), 2666-2675 (2005).
45. Nagai T, Tanaka M, Tsuneyoshi Y et al.: In vitro and in vivo efficacy of a recombinant immunotoxin against folate receptor β on the activation and proliferation of rheumatoid arthritis synovial cells. Arthritis Rheum. 54(10), 3126-3134 (2006).
46. Paulos CM, Varghese B, Widmer WR, Breur GJ, Vlashi E, Low PS: Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis. Arthritis Res. Ther. 8(3), R77 (2006).
47. Low PS, Henne WA, Doorneweerd DD: Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc. Chem. Res. 41(1), 120-129 (2008).
48. Gibbs DD, Theti DS, Wood N et al.: BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to α-folate receptor-overexpressing tumors. Cancer Res. 65(24), 11721-11728 (2005).
49. Nagayoshi R, Nakamura M, Ijiri K, Yoshida H, Komiya S, Matsuyama T: LY309887, antifolate via the folate receptor suppresses murine type II collagen-induced arthritis. Clin. Exp. Rheumatol. 21(6), 719-725 (2003).
50. Chintalacharuvu S, Evans GF, Shih C, Bryant HU, Sandusky GE, Zuckerman SH: Inhibition of glycinamide ribonucleotide formyltransferase results in selective inhibition of macrophage cytokine secretion in vitro and in vivo efficacy in rat adjuvant arthritis. Clin. Exp. Rheumatol. 23(4), 438-446 (2005).
51. Andersson SE, Johansson LH, Lexmuller K, Ekstrom GM: Anti-arthritic effect of methotrexate: is it really mediated by adenosine? Eur. J. Pharm. Sci. 9(4), 333-343 (2000).
52. Van der Heijden JW, Gerards AH, Oerlemans R et al.: Inhibition of tumour necrosis factor α production by activated T cells of rheumatoid arthritis patients by novel anti-folate drugs: an ex vivo pilot study. Arthritis Res. Ther. 7(Suppl. 1), S32-S33 (2005).
53. Whittle SL, Hughes RA: Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford) 43(3), 267-271 (2004).
54. Arabelovic S, Sam G, Dallal GE et al.: Preliminary evidence shows that folic acid fortification of the food supply is associated with higher methotrexate dosing in patients with rheumatoid arthritis. J. Am. Coll. Nutr. 26(5), 453-455 (2007).
55. Smith AD, Kim YI, Refsum H: Is folic acid good for everyone? Am. J. Clin. Nutr. 87(3), 517-533 (2008).
56. Blaser BW, Gonit M, Qi H et al.: Induction of folate receptor type β in a bone marrow engraftment model of acute myelogenous leukemia. Leukemia 21(10), 2233-2235 (2007).
57. Qi H, Ratnam M: Synergistic induction of folate receptor β by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates. Cancer Res. 66(11), 5875-5882 (2006).
58. Tran T, Shatnawi A, Zheng X, Kelley KM, Ratnam M: Enhancement of folate receptor α expression in tumor cells through the glucocorticoid receptor: a promising means to improved tumor detection and targeting. Cancer Res. 65(10), 4431-4441 (2005).
59. van der Laken CJ, Elzinga EH, Kropholler MA et al.: Noninvasive imaging of macrophages in rheumatoid synovitis using 11C-(R)-PK11195 and positron emission tomography. Arthritis Rheum. 58(11), 3350-3355 (2008).